July 2019 Br J Cardiol 2019;26(suppl 2):S20–S23 doi:10.5937/bjc.2019.s12
Nigel Rowell
Introduction Three important lines of evidence have informed the debate on optimal anticoagulation for people at risk of stroke: Meta-analyses have generally supported the findings from the ENGAGE-AF TIMI-481 and Hokusai-VTE2 trials, in terms of comparable efficacy and reduced bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients at risk of stroke, or with acute venous thromboembolism (VTE), respectively.3-8 The randomised Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA) trial confirmed the superiority of anticoagulation versus aspirin in elderly patients with atrial fibrillati
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits